Translational Neuroimaging, Division of Psychiatry, Institute of Mental Health, University of Nottingham and Nottinghamshire Healthcare National Health Service Trust, Nottingham, England.
JAMA Psychiatry. 2013 Oct;70(10):1031-40. doi: 10.1001/jamapsychiatry.2013.203.
At present, no reliable predictors exist to distinguish future responders from nonresponders to treatment during the first episode of psychosis. Among potential neuroimaging predictors of treatment response, gyrification represents an important marker of the integrity of normal cortical development that may characterize, already at illness onset, a subgroup of patients with particularly poor outcome.
To determine whether patients with first-episode psychosis who do not respond to 12 weeks of antipsychotic treatment already have significant gyrification defects at illness onset.
Case-control study with 12 weeks' longitudinal follow-up to determine treatment response.
Secondary psychiatric services in an inner-city area (South London, England).
A total of 126 subjects, including 80 patients presenting with first-episode psychosis and 46 healthy controls. Patients were scanned at the outset and received various antipsychotic medications in a naturalistic clinical setting. They were followed up for 12 weeks and classified as responders or nonresponders if they reached criteria for symptom remission, evaluated with the Psychiatric and Personal History Schedule.
Patients were exposed to naturalistic antipsychotic treatment for 12 weeks following a magnetic resonance imaging scan.
Cortical gyrification was assessed using local gyrification index in a vertexwise fashion across the entire cortical surface with correction for multiple testing using permutation analysis. Differences in local gyrification index were assessed between responders, nonresponders, and healthy controls. The effect of diagnosis (affective vs nonaffective psychosis) on the local gyrification index was also investigated in responders and nonresponders.
Patients with first-episode psychosis showed a significant reduction in gyrification (hypogyria) across multiple brain regions compared with healthy controls. Interestingly, nonresponders showed prominent hypogyria at bilateral insular, left frontal, and right temporal regions when compared with responders (all clusters significant at P < .05). These effects were present for both affective and nonaffective psychoses.
Gyrification appears to be a useful predictor of antipsychotic treatment response. Early neurodevelopmental aberrations may predict unfavorable prognosis in psychosis, irrespective of the existing diagnostic boundaries.
目前,在精神病首次发作期间,尚无可靠的预测指标可区分未来的治疗反应者和非反应者。在治疗反应的潜在神经影像学预测指标中,脑回形成代表了正常皮质发育完整性的重要标志物,它可能已经在疾病发作时,就表现出一组预后特别差的患者。
确定在接受 12 周抗精神病药物治疗后无反应的首发精神病患者,在发病时是否已经存在明显的脑回缺陷。
病例对照研究,进行 12 周的纵向随访以确定治疗反应。
位于市区(英国伦敦南部)的二级精神科服务机构。
共有 126 名受试者,包括 80 名首发精神病患者和 46 名健康对照者。患者在发病时接受扫描,并在自然临床环境中接受各种抗精神病药物治疗。他们接受了 12 周的随访,如果他们达到症状缓解的标准,就会被分类为反应者或无反应者,该标准使用精神病和个人病史表进行评估。
患者在磁共振成像扫描后接受了为期 12 周的自然抗精神病治疗。
使用顶点式局部脑回指数在整个皮质表面评估皮质脑回形成,并用置换分析校正多重检验。在反应者、无反应者和健康对照组之间,评估局部脑回指数的差异。还在反应者和无反应者中,研究了诊断(情感性与非情感性精神病)对局部脑回指数的影响。
首发精神病患者与健康对照组相比,多个脑区的脑回形成(脑回减少)显著减少。有趣的是,与反应者相比,无反应者双侧岛叶、左侧额叶和右侧颞叶的脑回减少更为明显(所有聚类在 P<.05 时均有意义)。这些影响在情感性和非情感性精神病中均存在。
脑回形成似乎是抗精神病药物治疗反应的有用预测指标。早期神经发育异常可能预测精神病预后不良,而与现有的诊断界限无关。